Lead Product(s) : RLYB331
Therapeutic Area : Hematology
Study Phase : Preclinical
Sponsor : Rallybio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Rallybio plans to prosecute preclinical activities for KY1066/RLYB331 including CMC, and dose-range finding and toxicity studies, which will then support transition of the asset into clinical development.
Brand Name : KY1066
Molecule Type : Large molecule
Upfront Cash : $3.0 million
May 10, 2022
Lead Product(s) : RLYB331
Therapeutic Area : Hematology
Highest Development Status : Preclinical
Sponsor : Rallybio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : T-Cell Therapy
Therapeutic Area : Hematology
Study Phase : Preclinical
Sponsor : Bristol Myers Squibb
Deal Size : $3,610.0 million
Deal Type : Collaboration
Prime Medicine and Bristol Myers Partner On Ex Vivo T-Cell Therapies
Details : The collaboration combines Prime Medicine’s precise, multiplex gene editing capabilities with BMS’s broad expertise in development and commercialization of novel ex vivo T-cell therapies.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
September 30, 2024
Lead Product(s) : T-Cell Therapy
Therapeutic Area : Hematology
Highest Development Status : Preclinical
Sponsor : Bristol Myers Squibb
Deal Size : $3,610.0 million
Deal Type : Collaboration
Lead Product(s) : T-Cell-based Therapy
Therapeutic Area : Hematology
Study Phase : Preclinical
Sponsor : Bristol Myers Squibb
Deal Size : $3,610.0 million
Deal Type : Collaboration
BMS Pays Prime $110M to Form T-cell Therapy Pact
Details : Prime Medicine will design optimized Prime Editor reagents for a select number of targets, including reagents that use its Prime Assisted Site-Specific Integrase Gene Editing (PASSIGE™) technology.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : $110.0 million
September 30, 2024
Lead Product(s) : T-Cell-based Therapy
Therapeutic Area : Hematology
Highest Development Status : Preclinical
Sponsor : Bristol Myers Squibb
Deal Size : $3,610.0 million
Deal Type : Collaboration
Lead Product(s) : Ex-vivo NK Cell Therapy
Therapeutic Area : Hematology
Study Phase : Preclinical
Sponsor : Sanofi
Deal Size : $1,240.0 million
Deal Type : Expanded Collaboration
Details : Under the collaboration, Sanofi receives an exclusive license to use Scribe’s CRISPR X-Editing (XE) genome editing technologies for the development of in vivo NK-cell therapies, including sickle cell disease.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : $40.0 million
July 17, 2023
Lead Product(s) : Ex-vivo NK Cell Therapy
Therapeutic Area : Hematology
Highest Development Status : Preclinical
Sponsor : Sanofi
Deal Size : $1,240.0 million
Deal Type : Expanded Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Hematology
Study Phase : Preclinical
Sponsor : DanausGT Biotechnology
Deal Size : Undisclosed
Deal Type : Collaboration
Details : This collaboration will accelerate the development of innovative therapeutics for the treatment of some diseases such as blood, skin, and liver-related diseases.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 02, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Hematology
Highest Development Status : Preclinical
Sponsor : DanausGT Biotechnology
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Blood Stem cell-based Therapy
Therapeutic Area : Hematology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $62.0 million
Deal Type : Series B Financing
Fly Like an Eagle: Garuda Brings in A $62M Series B
Details : The Series B funds will funnel into two programs Blood stem cell-based therapy, slated to hit the clinic in 2024 - transfusion-dependent beta-thalassemia (TDBT) in Europe and bone marrow failure syndrome in Europe, South America and North America
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
February 07, 2023
Lead Product(s) : Blood Stem cell-based Therapy
Therapeutic Area : Hematology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $62.0 million
Deal Type : Series B Financing
Lead Product(s) : DISC-0998
Therapeutic Area : Hematology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DISC-0998 is an investigational anti-HJV mAb with an engineered Q and L mutation (QL-mutation) in the Fc region, aimed to alter binding to the FcRn receptor, resulting in an increased PK half-life.
Brand Name : DISC-0998
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 03, 2022
Lead Product(s) : DISC-0998
Therapeutic Area : Hematology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : VMX-C001
Therapeutic Area : Hematology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
First Subjects Dosed in First-in-Human Trial for VarmX’s Anticoagulant Reversal Agent, VMX-C001
Details : Company announced treatment of the first subjects in its first-in-human study for lead compound VMX-C001able to rapidly and effectively restore coagulation in the presence of FXa DOAC, the Trial will assess safety, tolerability, PK and PD.
Brand Name : VMX-C001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 15, 2021
Lead Product(s) : VMX-C001
Therapeutic Area : Hematology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable